Jonathan L. Guarino, the Chief Financial Officer of Soligenix, Inc., has voluntarily surrendered stock options for cancellation. This decision, made on October 12, 2026, involves an aggregate of 914 shares of Common Stock with varying exercise prices. The surrender reflects a strategic move within the company as it continues to operate in the competitive pharmaceutical preparations sector.
Soligenix, Inc. is a biopharmaceutical company focused on developing products to treat rare diseases and conditions. The company operates under the Standard Industrial Classification of Pharmaceutical Preparations. It is incorporated in Delaware and has its business address in Princeton, New Jersey. The company is publicly traded under the ticker symbol SNGX.
According to the filing, Guarino's surrender of stock options is exempt from Section 16(b) of the Exchange Act due to the nature of the transaction. The filing states, "On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 914 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration." This indicates a deliberate choice by Guarino, possibly to align management interests with those of shareholders.
This action may affect various stakeholders, including shareholders and employees, as it signals a commitment to prudent financial management. The cancellation of these options could influence the company's future compensation strategies and employee morale.
The filing does not say what happens next.